Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

External quality assessment of noninvasive fetal RHD genotyping

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Determinants of intention to return to donate blood among first-time blood donors in Ghana

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. How donor selection criteria can be evaluated with limited scientific evidence: lessons learned from the TRANSPOSE project

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Putting the spotlight on donation-related risks and donor safety - are we succeeding in protecting donors?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Impact of long-term storage of plasma and cell-free DNA on measured DNA quantity and fetal fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Freeze-dried plasma in major haemorrhage: a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Impact of long-term storage of plasma and cell-free DNA on measured DNA quantity and fetal fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Targeted Rhesus immunoglobulin for RhD negative women undergoing an induced abortion: a clinical pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Blood group genotyping of blood donors: validation of a highly accurate routine method

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND AND OBJECTIVES: Fetal RHD genotyping of cell-free maternal plasma DNA from RhD negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 31 laboratories.

MATERIALS AND METHODS: Aliquots of pooled maternal plasma from gestational week 25 were sent to each laboratory. One sample was fetal RHD positive, and a second sample was fetal RHD negative. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. The samples were tested blindly.

RESULTS: Different methodological approaches were used; 29 laboratories used qPCR and two laboratories used ddPCR, employing a total of eight different combinations of RHD exon targets. Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD positive sample. All clinical conclusions were satisfactory.

CONCLUSION: This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting.

OriginalsprogEngelsk
TidsskriftVox Sanguinis
Vol/bind115
Udgave nummer5
Sider (fra-til)466-471
Antal sider6
ISSN0042-9007
DOI
StatusUdgivet - jul. 2020

Bibliografisk note

© 2020 International Society of Blood Transfusion.

ID: 61695612